Dapagliflozin and cardiovascular outcomes in type 2 diabetes SD Wiviott, I Raz, MP Bonaca, O Mosenzon, ET Kato, A Cahn, ... New England Journal of Medicine 380 (4), 347-357, 2019 | 5891 | 2019 |
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome … TA Zelniker, SD Wiviott, I Raz, K Im, EL Goodrich, MP Bonaca, ... The Lancet 393 (10166), 31-39, 2019 | 2650 | 2019 |
Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal … TA Zelniker, SD Wiviott, I Raz, KA Im, EL Goodrich, RHM Furtado, ... Circulation 139 (17), 2022-2031, 2019 | 702 | 2019 |
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial O Mosenzon, SD Wiviott, A Cahn, A Rozenberg, I Yanuv, EL Goodrich, ... The lancet Diabetes & endocrinology 7 (8), 606-617, 2019 | 679 | 2019 |
Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus ET Kato, MG Silverman, O Mosenzon, TA Zelniker, A Cahn, RHM Furtado, ... Circulation 139 (22), 2528-2536, 2019 | 623 | 2019 |
Dapagliflozin and cardiovascular outcomes in patients with type 2 diabetes mellitus and previous myocardial infarction: subanalysis from the DECLARE-TIMI 58 Trial RHM Furtado, MP Bonaca, I Raz, TA Zelniker, O Mosenzon, A Cahn, ... Circulation 139 (22), 2516-2527, 2019 | 338 | 2019 |
Effect of saxagliptin on renal outcomes in the SAVOR-TIMI 53 trial O Mosenzon, G Leibowitz, DL Bhatt, A Cahn, B Hirshberg, C Wei, KA Im, ... Diabetes care 40 (1), 69-76, 2017 | 281 | 2017 |
The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 Trial SD Wiviott, I Raz, MP Bonaca, O Mosenzon, ET Kato, A Cahn, ... American heart journal 200, 83-89, 2018 | 180 | 2018 |
DECLARE‐TIMI 58: participants’ baseline characteristics I Raz, O Mosenzon, MP Bonaca, A Cahn, ET Kato, MG Silverman, ... Diabetes, Obesity and Metabolism 20 (5), 1102-1110, 2018 | 151 | 2018 |
Clinical considerations for use of initial combination therapy in type 2 diabetes A Cahn, WT Cefalu Diabetes Care 39 (Supplement_2), S137-S145, 2016 | 122 | 2016 |
New forms of insulin and insulin therapies for the treatment of type 2 diabetes A Cahn, R Miccoli, A Dardano, S Del Prato The Lancet Diabetes & Endocrinology 3 (8), 638-652, 2015 | 119 | 2015 |
Digital health technology and diabetes management: 数字化医疗技术与糖尿病管理 A Cahn, A Akirov, I Raz Journal of diabetes 10 (1), 10-17, 2018 | 111 | 2018 |
Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial LA Leiter, H Teoh, E Braunwald, O Mosenzon, A Cahn, KMP Kumar, ... Diabetes Care 38 (6), 1145-1153, 2015 | 111 | 2015 |
Efficacy and safety of dapagliflozin in the elderly: analysis from the DECLARE–TIMI 58 study A Cahn, O Mosenzon, SD Wiviott, A Rozenberg, I Yanuv, EL Goodrich, ... Diabetes care 43 (2), 468-475, 2020 | 107 | 2020 |
Acute renal outcomes with sodium‐glucose co‐transporter‐2 inhibitors: real‐world data analysis A Cahn, C Melzer‐Cohen, R Pollack, G Chodick, V Shalev Diabetes, Obesity and Metabolism 21 (2), 340-348, 2019 | 89 | 2019 |
Prediction of progression from pre‐diabetes to diabetes: development and validation of a machine learning model A Cahn, A Shoshan, T Sagiv, R Yesharim, R Goshen, V Shalev, I Raz Diabetes/metabolism research and reviews 36 (2), e3252, 2020 | 82 | 2020 |
An update on DPP-4 inhibitors in the management of type 2 diabetes A Cahn, S Cernea, I Raz Expert opinion on emerging drugs 21 (4), 409-419, 2016 | 74 | 2016 |
Metformin use and clinical outcomes among patients with diabetes mellitus with or without heart failure or kidney dysfunction: observations from the SAVOR-TIMI 53 trial BA Bergmark, DL Bhatt, DK McGuire, A Cahn, O Mosenzon, PG Steg, ... Circulation 140 (12), 1004-1014, 2019 | 73 | 2019 |
Incidence of fractures in patients with type 2 diabetes in the SAVOR-TIMI 53 trial O Mosenzon, C Wei, J Davidson, BM Scirica, I Yanuv, A Rozenberg, ... Diabetes care 38 (11), 2142-2150, 2015 | 72 | 2015 |
The effect of dapagliflozin on albuminuria in DECLARE-TIMI 58 O Mosenzon, SD Wiviott, HJL Heerspink, JP Dwyer, A Cahn, EL Goodrich, ... Diabetes Care 44 (8), 1805-1815, 2021 | 71 | 2021 |